MedPath

F. Hoffmann-La Roche Ltd.

🇨🇭Switzerland
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.roche.com

Clinical Trials

1.1k

Active:1011
Completed:58

Trial Phases

4 Phases

Phase 1:705
Phase 2:4
Phase 3:18
+1 more phases

Drug Approvals

3

NMPA:3

Drug Approvals

Peginterferon alfa-2a Solution for Injection

Product Name
派罗欣
Approval Number
国药准字J20160076
Approval Date
Sep 27, 2016
NMPA

Peginterferon alfa-2a Solution for Injection

Product Name
派罗欣
Approval Number
J20160076
Approval Date
Sep 27, 2016
NMPA

Trastuzumab Injection

Product Name
赫赛汀
Approval Number
S20160001
Approval Date
Jan 18, 2016
NMPA

Clinical Trials

Distribution across different clinical trial phases (814 trials with phase data)• Click on a phase to view related trials

Phase 1
705 (86.6%)
Not Applicable
86 (10.6%)
Phase 3
18 (2.2%)
Phase 2
4 (0.5%)
phase_1_2
1 (0.1%)

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Phase 3
Recruiting
Conditions
M329 Systemic lupus erythematosus, unspecified
Systemic lupus erythematosus, unspecified
M329
Last Posted Date
2024-08-20
Lead Sponsor
F. HOFFMANN-LA ROCHE LTD.
Target Recruit Count
112
Registration Number
PER-021-21

News

No news found
© Copyright 2025. All Rights Reserved by MedPath